|drug1025||Dexamethasone 2 MG/ML Wiki||1.00|
|drug530||Bromhexine Hydrochloride Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The investigator will select participants with moderate to severe covid 19 disease admitted in Fatima memorial hospital. The investigator will divide them in two groups according to convenience sampling. Group 1 will be given dexamethasone 8mg/day and group 2 will be given methylprednisolone 1mg/kg/day IV for 5 days. The investigator will compare the improvement in temperature, oxygen requirement and CRP level at day zero and day 5 in both the groups.
Description: reduction in temperature in degree farrenheitMeasure: temperature (F) Time: 5 days
Description: reduction in oxygen requirement in lit/minMeasure: oxygen saturation(%) Time: 5 days
Description: mean reduction in CRP mg/dl in 5 daysMeasure: CRP (mg/dl) Time: 5 days
Description: number of patients diedMeasure: mortality Time: 5 days
Description: number of patients shifted to ICUMeasure: ICU transfer Time: 5 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports